Japanese Encephalitis in Two Children -- United States, 2010

Chen, L.; Peek, M.; Stokich, D.; Todd, R.; Anderson, M.; Murphy, F. K.; Hoffman, R.; Evans, A.; Jordan-Villegas, A.; McCracken Jr., G.; Chung, W. M.; Tran, J.; Raj, P.; Shieh, W.-J.; Schmitz, A.; Zaki, S.; Hills, S. L.; Lambert, A.; Panella, A.; Laven, J.
March 2011
MMWR: Morbidity & Mortality Weekly Report;3/11/2011, Vol. 60 Issue 9, p276
The article discusses two cases of Japanese encephalitis in two children in the U.S. that occurred in 2010. According to the article, Japanese encephalitis virus (JEV) is the foremost cause of vaccine-preventable encephalitis in the Asia Pacific region. The first case involved a girl aged 11 years that was hospitalized in Nevada on July 18, 2010 after suffering from 2 days of fever, headache, nausea, vomiting, and neck pain. The second case involved a boy aged 6 years who has hospitalized in Texas for fever, somnolescence, and headache on July 14, 2010.


Related Articles

  • Japanese-encephalitis vaccine now available. Barnett, Robert // Travel & Leisure;Sep93, Vol. 23 Issue 9, p156 

    Reports on Food and Drug Administration's approval of JE-VAX, the vaccine for Japanese encephalitis. Recommended for travelers who will be in rural areas of Southeast Asia for more than a month; Mosquitoes as the source of the virus; Antimalarial precautions; Procedure of medication; Vaccine's...

  • Promising biotech vaccine to be tested. Mason, Peter W. // Agricultural Research;Oct94, Vol. 42 Issue 10, p31 

    Reports that gene-engineered vaccines for Japanese encephalitis will be field-tested in swine. Poxviruses used in the vaccine; Institutions responsible for the development of the vaccine.

  • Japanese Encephalitis Immunization in South Korea: Past, Present, and Future. Young Mo Sohn // Emerging Infectious Diseases;Jan/Feb2000, Vol. 6 Issue 1, p17 

    Japanese encephalitis (JE), once a major public health problem in South Korea, has declined since the 1980s, as a result of improved living conditions, a mosquito eradication program, and a national JE vaccination program, which includes annual booster vaccine for all children = 15 years of age....

  • New Japanese encephalitis vaccine more accessible to those in need.  // Infectious Disease News;Nov2013, Vol. 26 Issue 11, p24 

    The article reports on the availability of a vaccine against Japanese encephalitis in 2013.

  • Safety and Immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial Ki Wook Yun; Hoan Jong Lee; Jin Han Kang; Byung Wook Eun; Yae-Jean Kim; Kyung-Hyo Kim; Nam Hee Kim; Young Jin Hong; Dong Ho Kim; Hwang Min Kim; Sung-Ho Cha // BMC Infectious Diseases;2015, Vol. 15 Issue 1, p252 

    Background Although mouse brain-derived, inactivated Japanese encephalitis vaccines (JE-MBs) have been successfully used for a long time, potential rare neurological complications have prompted the development of a Vero cell culture-derived inactivated vaccine (JE-VC). In a phase III clinical...

  • Bill Gates boosts fight against virus that threatens three billion in Asia. Elliot, Amanda // BMJ: British Medical Journal (International Edition);12/13/2003, Vol. 327 Issue 7428, p1366 

    Discusses a five-year program funded by Microsoft billionaire Bill Gates in the fight against Japanese encephalitis, a debilitating virus which kills one in three of its victims. Long term disabilities which occurs in almost half of all cases; Children who represent one third of the victims and...

  • Any Questions?  // British Medical Journal;8/9/1975, Vol. 3 Issue 5979, p363 

    Presents a question-and-answer advisory related to medicine. Treatment of psittacosis in children; Immunization against Japanese encephalitis; Importance of regular vaccination of all hospital and public health department staff.

  • Biological E. launches JE vaccine.  // BioSpectrum;Oct2012, Vol. 10 Issue 10, p14 

    The article offers information on the JEEV vaccine launched by Biological E. Ltd. to protect adults and children from Japanese Encephalitis (JE) in India.

  • JE vax campaign could save Cambodia US$1.46 million.  // PharmacoEconomics & Outcomes News;6/26/2010, Issue 606, p9 

    The article discusses research on the cost effectiveness of Japanese encephalitis vaccine in Cambodia, referencing a study by S. Touch and colleagues published in the May 11, 2010 issue of "Vaccine."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics